KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.
Sponsor: Kartos Therapeutics, Inc.
This PHASE1/PHASE2 trial investigates Myelofibrosis and Post-ET Myelofibrosis and is currently ongoing. Kartos Therapeutics, Inc. leads this study, which shows 8 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE1/PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Unknown PHASE1/PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Aug 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 3 earlier versions
-
Sep 2021 — Jun 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Nov 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kartos Therapeutics, Inc.
- Telios Pharma, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amiens, France , Barcelona, Spain , Belgrade, Serbia , Birmingham, United States , Bologna, Italy , Brescia, Italy , Bydgoszcz, Poland , Florence, Italy , Foggia, Italy , Fort Lee, United States and 27 more locations